Humacyte Stock Current Valuation
| HUMAW Stock | USD 0.91 0.01 1.11% |
Valuation analysis of Humacyte helps investors to measure Humacyte's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to climb to about 255.9 M in 2025, despite the fact that Enterprise Value Over EBITDA is likely to grow to (2.40).
Fairly Valued
Today
Please note that Humacyte's price fluctuation is abnormally volatile at this time. Calculation of the real value of Humacyte is based on 3 months time horizon. Increasing Humacyte's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Humacyte stock is determined by what a typical buyer is willing to pay for full or partial control of Humacyte. Since Humacyte is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Humacyte Stock. However, Humacyte's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.91 | Real 0.87 | Hype 0.73 |
The intrinsic value of Humacyte's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Humacyte's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Humacyte helps investors to forecast how Humacyte stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Humacyte more accurately as focusing exclusively on Humacyte's fundamentals will not take into account other important factors: Humacyte Company Current Valuation Analysis
Humacyte's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Humacyte Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Humacyte is extremely important. It helps to project a fair market value of Humacyte Stock properly, considering its historical fundamentals such as Current Valuation. Since Humacyte's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Humacyte's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Humacyte's interrelated accounts and indicators.
Click cells to compare fundamentals
Humacyte Current Valuation Historical Pattern
Today, most investors in Humacyte Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Humacyte's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Humacyte current valuation as a starting point in their analysis.
Humacyte Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Humacyte has a Current Valuation of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Humacyte is currently under evaluation in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 855.47 Million. Humacyte adds roughly 0.0 in current valuation claiming only tiny portion of equities under Health Care industry.Humacyte Current Valuation Drivers
We derive many important indicators used in calculating different scores of Humacyte from analyzing Humacyte's financial statements. These drivers represent accounts that assess Humacyte's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Humacyte's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 126.6M | 289.8M | 217.4M | 293.7M | 264.3M | 179.5M | |
| Enterprise Value | 115.5M | 120.8M | 115.4M | 270.8M | 243.7M | 255.9M |
Humacyte Fundamentals
| Return On Equity | -8.51 | ||||
| Return On Asset | -0.53 | ||||
| Number Of Shares Shorted | 490 | ||||
| Gross Profit | (77.4 M) | ||||
| EBITDA | (96.46 M) | ||||
| Net Income | (110.78 M) | ||||
| Total Debt | 57.51 M | ||||
| Book Value Per Share | (0.53) X | ||||
| Cash Flow From Operations | (73.31 M) | ||||
| Earnings Per Share | (3.16) X | ||||
| Number Of Employees | 183 | ||||
| Beta | 1.36 | ||||
| Total Asset | 128.22 M | ||||
| Retained Earnings | (537.31 M) | ||||
| Working Capital | 64.83 M | ||||
| Net Asset | 128.22 M |
About Humacyte Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Humacyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Humacyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Humacyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.